Hydralazine
Quoted from the FDA label. Product labels differ by manufacturer and change over time; confirm against the label for the product you are using. Not yet reviewed by a ClinDose pharmacist.
Dosing in kidney impairment
Renal Impairment There are no studies of renal impairment using isosorbide dinitrate and hydralazine hydrochloride tablets. No dose adjustment is required for hydralazine or isosorbide dinitrite [see Clinical Pharmacology ] . Dialyzability of hydralazine has not been determined . Dialysis is not an effective method for removing isosorbide dinitrate or its metabolite isosorbide-5-mononitrate from the body.
Dosing in liver impairment
Hepatic Impairment The effect of hepatic impairment on the pharmacokinetics of hydralazine alone has not been determined. Isosorbide dinitrate concentrations increase in patients with cirrhosis. There are no studies of hepatic impairment using isosorbide dinitrate and hydralazine hydrochloride tablets.